Skip to main content

Case presentation of #patients hospitalised with #mpox (subclade Ib/2023sh) including #children, #adolescents, and #adults in South Kivu, #DRC: an observational cohort study

 


Summary

Background

Mpox is a public health concern in eastern DR Congo. It continues to cause substantial numbers of hospital admissions, with changing demographics including children and adolescents, requiring comprehensive clinical and epidemiological investigation. In this study, we aim to describe the clinical characteristics of hospitalised participants infected with monkeypox virus (MPXV) subclade Ib/2023sh in the Kabare Territory in South Kivu, DR Congo.

Methods

This observational cohort study included patients admitted with suspected mpox to the reference centre of mpox treatment at Lwiro Hospital, South Kivu, DR Congo. Eligible participants must have had, at the time of inclusion, skin lesions compatible with the infection. Individuals who did not present lesions compatible with MPXV infection were also eligible if they had at least one of the following symptoms: fever, cervical lymphadenopathy, or pharyngitis, provided they had been in contact with someone with suspected mpox within the last 21 days. Data from hospital records and standardised clinical forms captured demographics, presenting symptoms and signs, outcomes, and general clinical characteristics. Descriptive analyses and statistics summarised the clinical and epidemiological profiles of participants with molecular confirmation of MPXV subclade Ib/2023sh.

Findings

Between Aug 3, 2024, and Feb 8, 2025, MPXV subclade Ib/2023sh was detected in 494 (77%) of 643 participants with a median age of 9 years (IQR 2–24). Participants who were positive for MPXV subclade Ib/2023sh infection were more often female (290 [59%]) and were generally older (median 16 years [4–25]) than male participants (204 [41%]; median age 4 years [1–14]). 300 (61%) of 494 participants were aged 15 years or younger. Fever (444 [90%]), skin lesions or rash (391 [79%]), and dysphagia (279 [56%]) were the most prevalent symptoms. Children aged 0–5 years had a higher frequency of lesions on the head (84 [41%] of 203), face (67 [33%]), neck (23 [11%]), back (27 [13%]), arm (35 [17%]), palm of hand (35 [17%]), chest (46 [23%]), posterior aspect of thighs (40 [20%]), legs (25 [12%]), dorsal foot (45 [22%]), and oral cavity (37 [18%]). 117 (24%) participants had lesions in the oral cavity. Oral cavity and oropharynx swabs were able to detect MPXV subclade Ib/2023sh in the absence of assayable skin lesions.

Interpretation

The high proportion of children and adolescents (aged ≤15 years) differentiates our cohort from other clinical descriptions of the novel MPXV subclade Ib/2023sh. Given that, we hypothesise a demographic shift in the target population that contributes to the community spread of mpox in the South Kivu region of DR Congo. Targeted public health measures should consider ways to reduce transmission among children and adolescents.

Funding

Canadian Institutes of Health Research (CIHR), Canadian Foundation for Innovation, Research Nova Scotia, Dalhousie Medical Foundation, Moderna, Li-Ka Shing Foundation, European & Developing Countries Clinical Trials Partnership (EDCTP).

Translations

For the French, Swahili and Mashi translations of the abstract see Supplementary Materials section.

Source: 


Link: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00051-4/fulltext?rss=yes

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...